Biocon gets 4 observations from USFDA for Andhra Pradesh facility
The US Food and Drug Administration (USFDA) concluded a GMP inspection of the company's API facility (Site 5), located at Visakhapatnam, Andhra Pradesh, on June 21, 2024, the company said in a regulatory filing.
![Biocon gets 4 observations from USFDA for Andhra Pradesh facility](https://cdn.zeebiz.com/sites/default/files/2024/06/22/300966-biocon.jpg?im=FitAndFill=(1200,900))
Biotechnology player Biocon on Saturday said the US health regulator has issued four observations after inspecting its manufacturing plant in Andhra Pradesh.